natgillin/translations-raw huggingface dataset:
a device configured to calculate magnitude and a direction of gradient of a pixel value for each pixel of the band image; an isotropic blurring device; an isotropic blurring device configured to apply an isotropic smoothing filter to the original image to generate an isotropic blur image; 
(C) uređaj za izotropno zamagljenje (14) koji ima konfiguraciju za nanošenje izotropnog filtera za omekšavanje šuma na originalnu sliku (PO) u svrhu stvaranja izotropne zamagljene slike (P1);
A preferred method to provide aggregates suitable for the present invention comprises the step of incubating AB-1-42 peptides, AB-1-43 peptides, AB-3-42 or AB-p(E)3-42 peptides or less preferably to AB-peptides that are truncated at the C-terminus such as AB-1-40 peptide, at a pH of 2 to 9 for at least 20 min, preferably at least 1 h, especially at least 4 h. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se AGB-agregati pripravljaju pomoću inkubacije AB-1-42-peptida, AB-1-43-peptida, AB-3-42-peptida ili AG-p(E)3-42-peptida, s pH vrijednosti od 2 do 9, u vremenu od najmanje 20 min, poželjno najmanje od 1 sata, posebno pogodno od najmanje 4 sata.
The pest control device according to claim 12, wherein the preservative comprises one or more of: sodium benzoate, potassium sorbate, sodium salicilate and one or more parabens, benzoic acid, calcium benzoate, calcium propionate, ethyl parahydroxybenzoate, potassium benzoate, potassium propionate, propionic acid, propyl parahydroxybenzoate, or sodium propionate. 
Uređaj za suzbijanje štetočina prema bilo kojem od patentnih zahtjeva od 3 do 7, naznačen time da konzervans sadrži jedan ili više od sljedećih sastojaka: natrijev benzoat, kalij-sorbat, natrijev salicilat, i jedan ili više parabena, benzojevu kiselinu, kalcijev benzoat, kalcijev propionat, etil- parahidroksibenzoat, kalijev benzoat, kalijev propionat, propionsku kiselinu, propil - parahidroksibenzoat, natrijev propionat.
The composition for use of claims 1-6, wherein the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Blautia hydrogenotrophica. 
Sastav za upotrebu prema zahtjevima 1-6, gdje bakterijski soj ima 16s rRNK sekvencu koja je najmanje 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% identična sa 16s rTRNK sekvencom bakterijskog soja Blautia hydrogenotrophica.
that the gas distribution pipe (121) comprises at least one inlet unit (122.1, 122.2) that demonstrate openings (125) through which gas flows, where the inlet unit (122.1, 122.2) is designed such that the gas distribution pipe demonstrates the form of a truncated cone, 
- odacijev za distribuciju plina (121) sadrži najmanje jednu ulaznu jedinicu (122.1, 122.2) koja ima otvore (125) kroz koji plin teće, pri čemu je ulazna jedinica (122.1, 122.2) dizajnirana tako da cijev za distribuciju plina ima oblik krnjeg stošca,
The calibration curve was prepared by serial dilutions of the standard r-hIL-18BP to give a range from 20 ng/ml to 0.3 ng/ml in assay buffer for each assay. 
Baždarna krivulja pripravljena je serijskim rezrijeđivanjem standardnog r-hIL-18BP kaka bi se dobio raspon od 20 ng/ml do 0.3 ng/ml u puferu za svaki test.
a nucleotide sequence having an identity of 90% or more to a nucleotide sequence selected from among SEQ ID NOs: 1 - 54 (wherein uracil may be thymine), and 
nukleotidna sekvenca koja ima 90% ili više identiteta od nukleotidne sekvence odabrane od SEQ ID NO: 1 do SEQ ID NO:54 (pri čemu uracil može biti tiamin); i
a first connecting element which in a connected condition of the components is arrangeable on the first component and includes a spring element, and 
prvi element za spajanje (120), koji se u spojenom stanju komponenata nalazi na prvoj komponenti (102), i -
Use according to claim 1 characterized in that the glucocorticoid is fluticasone or a physiologically acceptable salt thereof. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je glukokortikoid flutikazon ili njegova fiziološki prihvatljiva sol.
The transmission method according to claim 1, wherein the search space only includes candidates for the localized allocation or only includes candidates for the distributed allocation. 
Metoda prijema sukladno jednom od zahtjeva 1 ili 2, naznačena time da je prostor pretraživanja konfiguriran u podatkovnom predjelu podokvira silazne veze.
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 100, 80, and 101 in which 1 or 2 amino acids are substituted, wherein said peptide induces a cytotoxic T cell specific to a cell expressing ETC2. 
Peptid koji može inducirati citotoksične T-stanice u skladu s patentnim zahtjevom 2, gdje se navedeni peptid sastoji od aminokiselinskog slijeda kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34 1 358, u kojem 1 ili 2 aminokiseline su zamijenjen ili dodan, naznačen time što navedeni peptid inducira citotoksične T-limfocite specifične za stanicu koja eksprimira CDH3.
An electrode structure in accordance with claim 1, characterized in that an outer jacket surface of a holding element and/or of an emission insert is inclined at an angle Y in the range 1° to 5°, preferably 1° to 3°, with respect to the middle longitudinal axis M and/or a chamfer is formed at a radially outer end face edge having an angle in the range 10° to 40°, preferably 10° to 20°. 
Struktura elektroda prema jednom od prethodnih zahtjeva, naznačena time da je vanjska površina ljuske (7.2.2, 7.2.4, 7.3.2) držača (7.2) 1/ili umetka za emisiju (7.3) nagnuta pod kutom y u rasponu 1* do 5%, poželjno 1? do 3% u odnosu na srednju uzdužnu os M i/ili zasjek s kutom u rasponu 10? do 40%, poželjno 10% do 20", konfiguriran radijalno prema van na prednjoj strani kuta.
A hand held medicine dosing and dispensing device according to Claim 25 wherein a visual analogue scale (VAS) is selectively displayed on the screen to facilitate the input of data. 
Ručni uređaj za doziranje 1 izdavanje lijeka prema zahtjevu 25 naznačen time da se vizualna analogna skala (VAS) selektivno prikazuje na zaslonu kako bi se olakšao unos podataka.
A pharmaceutical composition comprising 
Farmaceutski sastav koji sadrži
eluting the DsbA polypeptide from the cation exchange chromatography material to generate a cation exchange eluate comprising the purified DsbA polypeptide. 
eluiranje DsbA polipeptida iz materijala za kromatografiju kationskom izmjenom, kako bi se dobio eluat kationske izmjene koji sadrži pročišćeni DsbA, pri čemu DsbA sadrži najmanje 95% monomernog DsbA polipeptida.
The veterinary or agricultural composition of claim 1, wherein in the dihydroazole compound of formula (I), G is G-2. 
Veterinarski ili agrikulturni sastav prema zahtjevu 1, naznačen time, da G je G-2 u spoju dihidroazola formule (I).
The composition for use in delivering a functional nucleic acid according to claim 1, wherein the functional nucleic acid is a regulatory RNA. The composition for use in delivering a functional nucleic acid according to claim 2, wherein the regulatory RNA is selected from the group consisting of siRNA, miRNA, shRNA, antisense ssRNA, ribozyme, and decoy RNA. 
Postupak oblikovanja mini-stanica pripravka prema zahtjevu 1, obuhvaća u puferu zajedničku inkubaciju (A) mnoštva intaktnih, bakterijski dobivenih mini-stanica s (B) regulatornom RNA bez plazmida, pri čemu se dobiju mini-stanice koje sadrže tu regulatornu RNA, gdje se ta regulatorna RNA izabire iz grupe koja obuhvaća siRNA, MIRNA i shRNA.
While the rate of decomposition of omeprazole at normal storage conditions is lower, it is nevertheless desirable to obtain physical forms of omeprazole which exhibit improved stability. 
Iako je brzina raspadanja omeprazola na normalnim uvjetima skladištenja niža, i uz to je poželjno da se dobiju fizikalni oblici omeprazola koji pokazuju povećanu stabilnost.
These sanding elements are used for example for sanding and finishing, more particularly for polishing welds on metal workpieces. Description of Related Art 
Ovi elementi za brušenje se koriste, na primjer, za dovršavanje, još posebnije za poliranje zavarenih spojeva na komadima koji se proizvode.
In another exemplary embodiment of the indexed drug delivery device, the device further comprises a plurality of indexed members, each indexed member adapted to be complementary to a corresponding indexed member and non-complementary to a non-corresponding indexed member. In another exemplary embodiment of the indexed drug delivery device, one or more indexed members are predeterminately adapted to indicate the identity and canister concentration of the API. 
Indeksirani uređaj za ograničavanje sadržaja lijeka (24) prema zahtjevu 1, naznačen time da indeksirani uređaj za ograničavanje sadržaja lijeka sadrži mnoštvo indeksiranih elemenata, te je svaki indeksirani element prilagođen da bude komplementaran s odgovarajućim indeksiranim elementom i ne-komplementaran na ne-odgovarajući indeksirani element.
H-indazole-3-carboxamide compounds having the following general formula (I): wherein 
Spojevi 1H-indazol-3-karboksamida, naznačeni time, da imaju sljedeću opću formulu (I):
where R1-R13 are as defined herein; whereupon the compound of formula IB is isolated as the free base or a salt such as a pharmaceutically acceptable acid addition salt thereof. 
HR P20080274 T3 gdje su R'-R'* kako je to ovdje definirano; nakon čega se spoj formule IB izolira kao slobodna baza ili sol njezina sol, kao što je to farmaceutski prihvatljiva njezina kisela dodatna sol
According to the invention, the groove structures 4 of the plate-shaped composite structure are then filled with a filling medium before mechanical machining. 
Zatim se, prema izumu, brazdaste strukture 4 pločaste kompozitne strukture pune s punilom prije mehaničke strojne obrade.
The PET container of claim 8 wherein the second endothermic glass transition temperature has an enthalpy greater than 0.5. 
PET posuda iz patentnog zahtjeva 8 gdje temperatura drugog endotermnog prelaza stakla ima entalpiju veću od 0.5.
A method according to claim 11, comprising sending a signal specifying said control pattern to each power unit of the first group of power units. 
Postupak sukladno zahtjevu 11, koji uključuje slanje signala koji određuje navedeni kontrolni uzorak do svakog mrežnog uređaja prve skupine mrežnih uređaja.
A polypeptide comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 residues 1-567, wherein 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-4, sadrži najmanje 85% identičnu aminokiselinskoj sekvenci u skladu sa SEK ID BR:1 ili SEK ID BR:35.
represents a cyano group, a mono-C1-6 alkylamino group, a di-C1-6 alkylamino group, a C2-6 alkyl group optionally substituted by 1 to 3 halogen atoms, a C1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms or one hydroxyl group, a C1-6 alkoxy C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, or a C1-6 alkoxy C1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms; 
predstavlja skupinu cijano, skupinu mono-C1-6 alkilamino, skupinu di-C1-6 alkilamino, skupinu C2-6 alkil proizvoljno supstituiranu s 1 do 3 halogenih atoma, skupinu C1-6 alkoksi proizvoljno supstituiranu s 1 do 3 halogenih atoma ili jednu hidroksilnu skupinu, skupinu C1-6 alkoksi C1-6 alkil proizvoljno supstituiranu s 1 do 3 halogenih atoma, ili skupinu C1-6 alkoksi C1-6 alkoksi proizvoljno supstituiranu s 1 do 3 halogenih atoma;
or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, or polymorph thereof 
ili njegova farmaceutski prihvatljiva sol, solvat, tautomer, stereoizomer ili polimorf.
Then, at least one dissecting tool through one of said at least two laparoscopic trocars, and an area of the stomach is dissected. The volume filling device is then introduced into the abdominal cavity, and placed on the outside of the stomach wall. A pouch in the stomach wall for the device is created, and the device invaginated in said pouch by providing sutures or staples to the stomach wall, thereby positioning the volume filling device so that the volume of the food cavity is reduced in size by a volume substantially exceeding the volume of the volume filling device. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uređaj za rukovanje ima potkožni prekidač (38; 72; 80; 472), prilagođen za neinvazivno rukovanje ručnim pritiskanjem prekidača za rukovanje uređajem za rastezanje. Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni uređaj ima najmanje dva upravljiva uređaja za rastezanje (410b), prilagođena za rastezanje najmanje dva različita dijela stijenke želuca, gdje je uređaj prilagođen za postoperativno i nemvazivno upravljanje.
The compound for use of Claim 9 wherein the condition treated is Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes. 
Spoj u skladu s patentnim zahtjevom 3 ili upotreba u skladu s patentnim zahtjevom 4, gdje stanje je dijabetes tipa 2, dijabetes tipa 1, smanjena tolerancija glukoze, hiperglikemija, metabolički sindrom (sindrom X i/ili sindrom otpornosti na inzulin), glukozurija, metabolička acidoza, artritis, katarakta, dijabetička neuropatija, dijabetička nefropatija, dijabetička retinopatija, dijabetička kardiomiopatija, pretilost, stanja čpgoršana pretilošću, hipertenzija, hiperlipidemija, ateroskleroza, osteoporoza, osteopenija, fragilnost, gubitak koštane mase, lomovi kostiju, akutni koronarni sindrom, nizak rast zbog nedostatka hormona rasta, neplodnost zbog sindroma policističnih jajnika, anksioznost, depresija, nesanica, kronična zamorenost, epilepsija, poremećaji hranjenja, kronična bol, ovisnost o alkoholu, bolesti povezane s pokretljivošću crijeva, ulceracije, sindrom iritabilnih crijeva, sindrom crijevne upale; te sprječavanje napredovanja bolesti kod dijabetesa tipa 2.
The method according to claim 9, characterised in that the step of distributing the fibres comprises the step of spraying the fibres on the layer (2) of sheet material. 
Postupak prema zahtjevu 9, naznačen time da korak raspodijele vlakana sadrži korak raspršivanja vlakana na sloj (2) pločastog materijala.
4-(Trifluoromethyl)benzyl bromide ((91 µl, 0.59 mmol) is added and stirring continues while the reaction mixture gradually warmed up to room temperature overnight. 
Doda se 4-(trifluormetil)benzil bromid ((91 ul, 0,59 mmola) i miješanje se nastavi dok se reakcijska smjesa preko noći postupno zagrije na sobnu temperaturu.
The use of claim 8, wherein Z is optionally substituted phenyl or optionally substituted pyridyl. 
Primjena prema zahtjevu 8, pri čemu je Z opcijski supstituirani fenil ili opcijski supstituirani piridil.
a compound of the formula I or a pharmaceutically acceptable salt, solvate, hydrate or morphological form thereof, 
spoj formule I [image] I ili njegovu farmaceutski prihvatljivu sol, njegov solvat, hidrat ili njegov morfološki oblik,
A compound of formula I: wherein A is NH2 or OH; and B is H or NH2; or pharmaceutically acceptable salt or hydrate thereof, for use in the inhibition of a RNA viral polymerase. 
[image] naznačen time da A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, za primjenu u inhibiciji virusne RNK polimeraze izabrane iz grupe koja se sastoji od virusnih polimeraza orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae i coronaviridae.
This solution was added to the reaction flask and the flask was sealed and placed under hydrogen. 
Ova otopina je bila dodana u tikvicu za reakciju i ta tikvica je bila začepljena i stavljena pod vodik.
Surprisingly it has been found that compounds of formula (I) wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; have good activity against soybean rust diseases, such as diseases caused by Phakopsora pachyrhizi and/or Phakopsora meibomiae. 
(A) spoja formule (I) naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) barem jednog spoja odabranog iz skupine koja se sastoji od (Bl) - strobilurin fungicida.
A reversible, short-acting P2Y12 inhibitor for use in a method according to claim 1, wherein the cangrelor is administered as an intravenous infusion of between 0.5 and 2.0 µg/kg/min. 
Reverzibilni, kratko djelujući inhibitor P2Y,, za uporabu u postupku prema zahtjevu 1, naznačen time da se cangrelor daje kao intravenska infuzija u količini od između 0.5 i 2.0 ug/ke/min.
The magnetic drive (26) of claim 2, wherein the driving member is disposed coaxially with the electric motor (28) and wherein the driving member and the electric motor (28) share a common shaft (70). 
Magnetni pogon prema patentnom zahtjevu 12, naznačen time što pogonski element je smješten koaksijalno s elektromotorom i pri čemu pogonski element i elektromotor imaju zajedničku osovinu.
wherein a transmission delivery system descriptor including the identifier of the PLP, the identifier of the transmission system, and a guard interval field in a TS loop of the NIT maps transport streams to PLPs in data slices of the transmission systems. The apparatus according to claim 13, wherein a value of the guard interval is one of 1/128 and 1/64. The apparatus according to claim 13 or claim 14, wherein the NIT includes an identifier of a transport stream and an identifier of a network. 
Uređaj prema zahtjevu 13, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 µs na 4k brzih Fourierovih transformacija (FFT), mod za prijenosni sustav od 8 MHz širine pojasa i 448 x (8/6) µs na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa. Uređaj prema zahtjevu 13 ili 14, gdje NIT obuhvaća identifikator prijenosnog toka i identifikator mreže.
The push stick according to claim 1, wherein the signaling device comprises a wire-bound or a wireless communication interface, via which the flat contact signal can be transmitted. 
Potiskivač u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što signalni uređaj sadrži ožičeno ili po mogućnosti sučelje za bežičnu komunikaciju, putem kojeg se može poslati signal o ravnom kontaktu.
The evacuating means for the at least two thermoblocks can thereby be arranged to respectively selectively provide a fluid connection between the inlet side of the thermoblocks and an evacuating outlet. 
Mehanizam za pražnjenje najmanje dva termobloka može se podesiti tako da selektivno omogućuje odgovarajući fluidni kontakt između izlazne strane termoblokova i izlaza za pražnjenje.
Elastic vibrations are excited by use of a hydraulic vibration generator, by a cyclic change of pressure in liquid being supplied. 
Elastične vibracije se pobuđuju uporabom hidrauličnog generatora vibracija, cikličkom promjenom tlaka u tekućini koja se izvlači.
A dispenser according to claim 20 or claim 21, wherein the cam follower comprises two substantially rigid protrusions (18a, 18b) extending from the base, and the junction member sits atop the upper surface of the protrusions. 
Dispenzer sukladno zahtjevu 20 ili zahtjevu 21, naznačen time da se pratitelj brega sastoji od dva znatno rigidna izbočenja (18a, 18b) koja se protežu od baze, i spojni dio leži povrh gornje površine izbočenja.
Alternatively compounds of formula (I) wherein Y represents a carbonyl group may be prepared by oxydation of a compound of formula (I) wherein Y represents a methylene group substituted by a hydroxyl group according to methods well known to one skilled in the art. 
Alternativno se spojeve formule (1), gdje Y predstavlja karbonilnu skupinu, može dobiti oksidacijom spoja formule (I), gdje Y predstavlja metilensku skupinu, supstituiranu s hidroksilnom skupinom, postupcima dobro poznatim stručnjaku.
MTT solution was then tipped off, the plate gently tapped dry and the cells dissolved upon the addition of 100µl of DMSO. 
Otopina MTT-a se potom izlije, pločica nježno osuši tapšanjem i stanice resupsendiraju u 100 ul DMSO-a.
In another preferred embodiment, the content of the pharmacologically active agent according to the general formula (I) in the pharmaceutical dosage form according to the invention is within the range of 0.5±0.3 wt.-%, for example, 0.5±0.2 wt.-%, or even 0.5±0.1 wt.-%. 
Farmaceutski oblik doziranja za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što je farmakološki aktivno sredstvo prema općoj formuli (1) (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil-4',9'-dihidro-3'H- spiro[cikloheksan-1,1'-pirano[3,4,b]-indol]-4-amin,
an amino acid sequence having at least 90% homology to amino acids residues 20 to 130 of SEQ ID NO: 34. 
aminokiselinska sekvenca koja ima najmanje 90% homologije sa aminokiselinskim ostacima 20 do 130 iz sekv. id. br.: 32, 33 ili 34.
Known mixing members also have the major drawback of performing poorly when the scrapers are called upon to remove thicker and harder than normal ice-cream off the wall surface, on account, for example, of more intense cooling of the lateral wall of the bowl. 
Poznati članci za miješanje također imaju veći nedostatak da slabo djeluju kada se od strugala traži da s plohe stijenke odstrane gušći i tvrđi sladoled od normalnog iz razloga, na primjer, intenzivnijeg hlađenja bočne stijenke zdjele.
The process according to claim 1, characterized in that the furan derivative is 5-hydroxymethylfurfural. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je derivat furana 5-hidroksimetilfurfural.
wherein the first fastener is positioned on the proximal end of the distal housing part and the second fastener protrudes outwardly from the inner surface of the interface member, wherein a fastened connection is achieved only when the first mechanically coded interface device matches and interacts with the third mechanically coded interface device, 
Uređaj za isporuku lijeka prema zahtjevu 4, naznačen time da su navedena treća mehanički kodirana sredstva sučelja (11) smještena na proksimalnoj unutrašnjoj površini distalnog dijela kućišta (10), a navedena četvrta mehanički kodirana sredstva sučelja (22) su smještena na distalnoj unutrašnjoj površini proksimalnog dijela kućišta (20).
The composition of claim 1, 3 or 4 in which the chemical modification of the glycosaminoglycans, the hydrolysed glycosaminoglycans, the glycosamines of glycosaminoglycans or the blend of the different glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines of glycosaminoglycans is an esterification, or a deacetylation followed by an esterification and a carbamatation, or a deacetylation followed by a carbamatation with CC or PRE-CC. 
Sastav prema zahtjevu 1, 3 ii 4, u kojem kemijska modifikacija glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina iz glikozaminoglikana ili mješavine različitih glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina iz glikozaminoglikana je esterifikacija ili deacetilacija nakon koje slijedi esterifikacija i karbamatacija ili deacetilacija nakon koje slijedi karbamatacija s CC ili PRE-CC.